Could a simple hormone test spare thousands of women from chemo?

NCT ID NCT07671885

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether premenopausal women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy if their tumor responds well to hormone therapy before surgery. About 950 women will be randomly assigned to either standard surgery first or hormone therapy before surgery. Those whose tumors shrink enough on hormone therapy will receive only more hormone therapy after surgery, avoiding chemo. The goal is to see if this approach is just as effective at preventing cancer from coming back, while reducing the burden of chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

aromatase inhibitor and ovarian function suppression (hormone therapy), with or without chemotherapy

What this could lead to

If successful, this could allow many premenopausal women with intermediate-risk breast cancer to avoid chemotherapy and its side effects, relying only on hormone therapy.

What could go wrong

This is a large phase 3 trial, but it is still ongoing. The response-guided approach may not prove as effective as standard care, and some patients might still need chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, Japan

  • National Cancer Center Hospital East

    RECRUITING

    Kashiwa, Japan